Indian Court Lifts Curbs On Herceptin Biosimilars; Roche Sticks To Guns
Executive Summary
An Indian court has, in a seesaw turn, lifted certain restrictions pertaining to partners Biocon and Mylan’s biosimilar versions of Roche’s Herceptin (trastuzumab). Roche, though, doesn’t seem keen to back off just yet and continues to rake up issues around data requirements for biosimilars.
You may also be interested in...
More Cheer For Biocon-Mylan As Brazil Clears Biosimilar Trastuzumab
Biocon and Mylan have received approval in Brazil for the first biosimilar version of Roche’s Herceptin (trastuzumab). The partners hope to provide an “affordable” option, expanding access to the product in the Latin American nation.
More Cheer For Biocon-Mylan As Brazil Clears Biosimilar Trastuzumab
Biocon and Mylan have received approval in Brazil for the first biosimilar version of Roche’s Herceptin (trastuzumab). The partners hope to provide an “affordable” option, expanding access to the product in the Latin American nation.
Roche Fears 'Real' Biosimilar Competition Says Russia's Biocad
Russia's Biocad has lashed out against Roche after being at the receiving end of what it claims are the Swiss multinational's 'scare tactics' against biosimilar competition in Sri Lanka. Biocad says it intends to pursue damages in the Sri Lankan case while Roche, which is standing its ground, has moved the Supreme Court in the island nation.